{"ticker": {"uuid": "28e2ddc1-89ff-46e9-bb43-3304f4a90160", "symbol": "ELVN", "name": "Enliven Therapeutics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enliven Therapeutics stock hits 52-week high at 52.47 USD", "summary": "Enliven Therapeutics (ELVN) has reached a new 52-week high of $52.47, reflecting a significant year-to-date return of 236% and a 143.2% increase over the past year. Despite this surge, InvestingPro data suggests the stock appears overvalued relative to its Fair Value. The company", "url": "https://www.investing.com/news/company-news/enliven-therapeutics-stock-hits-52week-high-at-5247-usd-93CH-4793950", "source_name": "Investing.com", "published_at": "2026-07-15T17:11:44", "published_display": "15 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64", "summary": "H.C. Wainwright has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and increased the target price to $64. This indicates a positive outlook from the analyst firm regarding the company's future performance and stock value.", "url": "https://www.moomoo.com/news/post/72710505/hc-wainwright-maintains-enliven-therapeutics-elvnus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-11T04:11:44", "published_display": "11 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Enliven Therapeutics price target on trial data By Investing.com", "summary": "H.C. Wainwright increased its price target for Enliven Therapeutics (NASDAQ:ELVN) to $65 from $56, maintaining a Buy rating, following positive Phase 1 trial data for ELVN-001 in chronic myelogenous leukemia. The stock has seen a significant year-to-date surge, and analysts hold ", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-raises-enliven-therapeutics-price-target-on-trial-data-93CH-4727142", "source_name": "Investing.com Canada", "published_at": "2026-07-09T11:41:12", "published_display": "09 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Fell Out Of Russell Indexes, But Is The Valuation Already Rich?", "summary": "Enliven Therapeutics (ELVN) was recently removed from several Russell indexes, yet its share price has seen significant gains. Despite trading below the average analyst target, the company's Price-to-Book ratio of 7.8x is well above the industry average, suggesting a rich valuati", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-fell-out-of-russell-indexes-but-is", "source_name": "Simply Wall Street", "published_at": "2026-07-09T01:40:23", "published_display": "09 Jul 2026 01:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/enliven-therapeutics-insider-sold-shares-212154684.html", "source_name": "MT Newswires", "published_at": "2026-07-08T21:21:54+00:00", "published_display": "08 Jul 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) director sells 10,000 shares under 10b5-1 plan", "summary": "Enliven Therapeutics director Lori Anne Kunkel sold 10,000 shares of common stock on July 6, 2026, through two open-market transactions at weighted average prices of $50.8442 and $49.9834 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan establis", "url": "https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-ce6296e72f95.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:40:23", "published_display": "08 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Enliven Therapeutics Inc. (ELVN) Affects Rotational Strategy Timing", "summary": "This article analyzes Enliven Therapeutics Inc. (NASDAQ: ELVN) using AI models to determine its impact on rotational strategy timing. It highlights a near-term neutral sentiment amidst mid and long-term strength, identifying a mid-channel oscillation pattern and a significant ris", "url": "https://news.stocktradersdaily.com/news_release/1/How_Enliven_Therapeutics_Inc._ELVN_Affects_Rotational_Strategy_Timing_070726022202_1783405322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T02:22:00", "published_display": "07 Jul 2026 02:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Enliven Therapeutics Inc (ELVN)", "summary": "This article examines the historical performance of investing $1,000 in Enliven Therapeutics Inc (ELVN) over various timeframes, detailing the significant returns an investor would have seen. It also provides an in-depth company profile, outlining Enliven Therapeutics' focus on p", "url": "https://www.stocktitan.net/tools/stock-return-calculator/ELVN", "source_name": "Stock Titan", "published_at": "2026-07-04T08:09:10", "published_display": "04 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQSmUyaExTdlp0YzVEQUhncjVoeTNiRTR6cDJUalY2WUdwMk9KRUF6bGpMMk14aWlUU3Bud2FWbzFFaGRCRWhsMUdhZUtTWVg0bHlfVkZMVm5HZGF2dVJTemQ0RGFJSExrM3RnV3BQdzRMVDJRNWNnYkdRVFdNb3I0NEx0eFZsb3VyY1pIODJFUUVlM1BIbjVhSTE1VWpxMXhzMU9oNA?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELVN Maintained by Stifel -- Price Target Raised to $80", "summary": "Stifel maintained a \"Buy\" rating for Enliven Therapeutics (ELVN) and raised its price target from $60 to $80 on July 1, 2026, indicating optimism about the company's future. Despite this positive analyst outlook, ELVN has a low GF Score\u2122 of 28/100, primarily due to weak profitabi", "url": "https://www.gurufocus.com/news/8941185/elvn-maintained-by-stifel-price-target-raised-to-80", "source_name": "GuruFocus", "published_at": "2026-07-01T14:40:07", "published_display": "01 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jones Trading raises Enliven Therapeutics price target on CML trials By Investing.com", "summary": "Jones Trading has increased its price target for Enliven Therapeutics (NASDAQ:ELVN) to $70 from $45, reiterating a Buy rating. This adjustment follows a positive Phase I trial update for ELVN-001 in chronic myeloid leukemia (CML) and the company's decision to pursue first-line an", "url": "https://ng.investing.com/news/stock-market-news/jones-trading-raises-enliven-therapeutics-price-target-on-cml-trials-93CH-2577860", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T00:11:55", "published_display": "30 Jun 2026 00:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jones Trading raises Enliven Therapeutics price target on CML trials", "summary": "Jones Trading increased its price target for Enliven Therapeutics (NASDAQ:ELVN) from $45 to $70, while maintaining a Buy rating, based on a positive Phase I update for its CML trials. The biotech company's stock has surged 214% in six months, and Jones Trading revised its model t", "url": "https://www.investing.com/news/analyst-ratings/jones-trading-raises-enliven-therapeutics-price-target-on-cml-trials-93CH-4765132", "source_name": "Investing.com", "published_at": "2026-06-29T23:10:36", "published_display": "29 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%", "summary": "", "url": "https://finance.yahoo.com/m/485cc147-72f1-3755-90ef-1f9d33a6bec5/what-to-know-about-this.html", "source_name": "Motley Fool", "published_at": "2026-06-27T19:56:42+00:00", "published_display": "27 Jun 2026 19:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally", "summary": "OrbiMed Advisors, a significant shareholder in Enliven Therapeutics (NASDAQ: ELVN), recently sold 860,123 shares worth approximately $39 million. This sale represents an 11.60% reduction in their indirect holdings but still leaves OrbiMed as a major shareholder with over 6.5 mill", "url": "https://finance.yahoo.com/markets/stocks/articles/know-orbimeds-39-million-enliven-162312437.html", "source_name": "Market source", "published_at": "2026-06-27T12:23:00", "published_display": "27 Jun 2026 12:23", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics, Inc. Actuals & Estimates (NASDAQ:ELVN)", "summary": "This article provides an overview of Enliven Therapeutics, Inc. (NASDAQ: ELVN) stock performance, financial data, and analyst forecasts. It includes current stock price, historical highs and lows, market capitalization, earnings per share, revenue, and upcoming earnings report da", "url": "https://www.tradingview.com/symbols/NASDAQ-ELVN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:12", "published_display": "26 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELVN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and various financial metrics for Enliven Therapeutics, Inc. (ELVN) stock. It includes analyst price targets, historical price performance, volatility, market capitalization, upcoming earnings dates, and past financial results like EPS and revenue", "url": "https://www.tradingview.com/symbols/NASDAQ-ELVN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:12", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "22% Below Analyst Target, Is Enliven Therapeutics (ELVN) Fairly Valued Here", "summary": "Enliven Therapeutics (ELVN) is currently valued at US$2.9 billion with shares at US$49.12, showing strong recent performance. Despite being loss-making and having a value score of 2, its Price-to-Book ratio of 6.6x is below its peer average but significantly above the broader US ", "url": "https://www.sahmcapital.com/news/content/22-below-analyst-target-is-enliven-therapeutics-elvn-fairly-valued-here-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-25T10:10:57", "published_display": "25 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed funds trim Enliven Therapeutics (NASDAQ: ELVN) stake with 860K-share sale", "summary": "OrbiMed-affiliated entities have reduced their stake in Enliven Therapeutics (NASDAQ: ELVN) by selling 860,123 shares on June 22, 2026, at prices ranging from $45 to $45.38 per share. Despite this sale, the funds still retain significant indirect holdings, with one fund holding o", "url": "https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-d05427e0374a.html", "source_name": "Stock Titan", "published_at": "2026-06-25T00:41:20", "published_display": "25 Jun 2026 00:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed entities sell $39 million in Enliven Therapeutics stock", "summary": "OrbiMed entities, including OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital GP VII LLC, sold approximately $39 million worth of Enliven Therapeutics (NASDAQ:ELVN) common stock on June 22, 2026. The sale involved 860,123 shares at prices between $45.00 and $45.38", "url": "https://www.investing.com/news/insider-trading-news/orbimed-entities-sell-39-million-in-enliven-therapeutics-stock-93CH-4759435", "source_name": "Investing.com", "published_at": "2026-06-24T23:41:20", "published_display": "24 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed cuts Enliven Therapeutics (ELVN) holdings to 9.5% of shares", "summary": "OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Enliven Therapeutics (ELVN) to 9.5% of outstanding shares, as reported in an Amendment No. 5 to their Schedule 13D filing. This reduction stems from open-market sales of Enliven shares by OPI VII,", "url": "https://www.stocktitan.net/sec-filings/ELVN/schedule-13d-a-enliven-therapeutics-inc-amended-major-shareholder-rep-2b58ce8978a9.html", "source_name": "Stock Titan", "published_at": "2026-06-24T23:41:20", "published_display": "24 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?", "summary": "Orbimed Advisors, a medical and biotech-focused hedge fund, recently sold 281,408 shares of Enliven Therapeutics Inc. (ELVN) for approximately $12.67 million, representing 3.67% of its indirect holdings. This transaction follows the biotech company's announcement of promising dat", "url": "https://www.fool.com/coverage/filings/2026/06/24/medical-hedge-fund-sells-281-000-shares-of-enliven-theapeutics-is-it-time-to-sell-elvn/", "source_name": "The Motley Fool", "published_at": "2026-06-24T19:39:24", "published_display": "24 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Enliven Therapeutics, Inc. Stocks", "summary": "This article lists various ETFs that invest in Enliven Therapeutics, Inc. (ELVN) stocks, providing detailed information such as market value, weight, issuer, management style, expense ratio, and assets under management for each fund. The ETFs primarily focus on small-cap, health ", "url": "https://www.tradingview.com/symbols/NASDAQ-ELVN/etfs/", "source_name": "TradingView", "published_at": "2026-06-24T02:39:24", "published_display": "24 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics stock hits 52-week high at 48.55 USD", "summary": "Enliven Therapeutics Inc. has achieved a significant milestone, with its stock reaching a 52-week high of $48.55 and currently trading at $48.72, boasting a 198% year-to-date return. This strong performance is supported by recent successful public offerings totaling around $460 m", "url": "https://m.uk.investing.com/news/stock-market-news/enliven-therapeutics-stock-hits-52week-high-at-4855-usd-93CH-4740977?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T21:10:48", "published_display": "23 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics CFO Hohl sells $263,577 in stock", "summary": "Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of the company's common stock for $263,577 on June 17, 2026, executed under a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high, generating a 193% year-to-date return. Prior to t", "url": "https://www.investing.com/news/insider-trading-news/enliven-therapeutics-cfo-hohl-sells-263577-in-stock-93CH-4754069", "source_name": "Investing.com", "published_at": "2026-06-23T08:10:48", "published_display": "23 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) CFO sells 6,018 shares after option exercise", "summary": "Enliven Therapeutics (ELVN) CFO Benjamin Hohl exercised stock options for 6,018 shares at $2.48 each and subsequently sold all 6,018 shares in open-market transactions on June 17, 2026, at weighted average prices between $42.79 and $44.75. These transactions were executed under a", "url": "https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-d881b9ab7a77.html", "source_name": "Stock Titan", "published_at": "2026-06-23T08:10:48", "published_display": "23 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Insider Sold Shares Worth $263,577, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/enliven-therapeutics-insider-sold-shares-211853820.html", "source_name": "MT Newswires", "published_at": "2026-06-22T21:18:53+00:00", "published_display": "22 Jun 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Enliven Therapeutics Inc For: 22 June By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Enliven Therapeutics Inc. on June 22. It is a brief, one-line report with a reference to Reuters. The article includes various market data, news headlines, and promotional content from Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-for-22-june-93CH-4702014", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:41:20", "published_display": "22 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics CMO sells $219,016 in shares", "summary": "Helen Louise Collins, CMO of Enliven Therapeutics (NASDAQ:ELVN), sold 4,900 shares for $219,016 on June 17, 2026, executed under a Rule 10b5-1 trading plan. These sales followed the exercise of stock options for 5,000 shares. The company's stock is trading near its 52-week high a", "url": "https://www.investing.com/news/insider-trading-news/enliven-therapeutics-cmo-sells-219016-in-shares-93CH-4754070", "source_name": "Investing.com", "published_at": "2026-06-22T21:41:19", "published_display": "22 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) CMO exercises 5,000 options and sells 5,000 shares", "summary": "Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised 5,000 stock options at $2.48 per share and subsequently sold 5,000 shares of common stock in three open-market transactions on June 17, 2026. The sales were conducted under a pre-arranged Rule 10b5-1 tra", "url": "https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-c568aee93b0f.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:41:19", "published_display": "22 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polar Capital (NASDAQ: ELVN) reports 8.46% stake in Enliven Therapeutics", "summary": "Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have jointly reported an 8.46% beneficial ownership stake in Enliven Therapeutics (NASDAQ: ELVN). This stake amounts to 5,056,807 shares of common stock, based on Enliven Therapeutics'", "url": "https://www.stocktitan.net/sec-filings/ELVN/schedule-13g-a-enliven-therapeutics-inc-amended-passive-investment-di-0e62afd9ab3a.html", "source_name": "Stock Titan", "published_at": "2026-06-22T13:40:12", "published_display": "22 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELVN (Nasdaq) selling holders report proposed sale, recent 272,322-share disposition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNcmROUE1ITWJjRnBnNzcteXpOLXlzR3VydDREaEhpTWs1eXFNajdRVTBXVGJ5YUZOSzNSQnNxcC1lVl92bHNybjlrNF9Qb0ktN25DWVh2WVVSUV9ORW9JbVNnQkpTQndxWlNIbWFUTGJjemJMTHQyeDJ2ZWh1RGNCZjZ2NEZXX3VpaDdxWjVmYzI1SVJMSGNVdEtfeHVIYUNESzVz?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed funds trim Enliven Therapeutics (ELVN) stake with 281,408-share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWnNDYUlZUTBqbElUNThQTTFRVWM3d19BY3BCNGJ2YXJnZTdUNUFUQTBvNkNPSi11aE0zQm10RG1hdlB5SEpaQ1F5RnVSZjBybUoxWmFQQWdvamdabFVhV3N6ZEMzZGdRQ1llcnlqRlVBVVFVaHY0TzVhbXZYTi1PSEJmZmZOUmRuOG16UzNMR3ZBUXlUS0dPa3J4TDlIT3RKZ2FfMjZsaDJXU25hQTNmajk3WklDWEc4ZHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Closes Upsized $460 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enliven-therapeutics-closes-upsized-460-210131835.html", "source_name": "MT Newswires", "published_at": "2026-06-15T21:01:31+00:00", "published_display": "15 Jun 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wJBVV95cUxPSWZ3TkoxUDN0bjVMZnNCdXhGejBxWXZCS0I5NnpHRGhvOFVDdjJJa19IamYyWDktZ1BJanl5VldXNTlWdHhVQ3Q1akhnZFA3RXdLamVDZ1dEWnowVS1Da2pKWmF6cUg3QUdWbzk2YzlzMUgwWEt5QzUxT1BONWgybEdSaWFScENGRExiMHBHcHdvZEd3THBTSk45OFdYNkEyeTdOMFNoMzhhQWd4dzVPNEZSaG9rWTlWYmV4OG1lTFNsVDB4aEUyQ2x5Z3N3YXZyZy1Nb2ZrT2hWTEJpc2Q5ZHNHcW0xM0s5Q0xNckxZaWdreThIaVZkS25oSE1ZVHZ1NVd1MHVKWFJJOU9pb3E5eUVveXNXVkY2bnkyV0tYamswTUgzT0puNy1PWlRJTVhDVTNKUFM4S2VpbzdrUU1tVkFmRGt5QmM5c2xScmJxekVaamZ0RGJ3?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Enliven just raised $460M in stock and warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQdWRoclo0UXBwckt0VUhiYVBDYnM1N19jb3JhbHFUYVUzTDUzM0dHMzRKMG1rUkQyMjJUR3h2WDFxS0F3Z2FqMFRMNnVEeVJiVUtxUzZLU09VNkJEZ3U4VUJYQ0U4TXpMU0dRY0Q3d05wRFVfOU9WUjNBRVpNbW5sVkpjNVZENEZqcW5BaHVrMFp5Z0dNYzIxWXlORkFuWWt0MFZPQ1BQSzV4MnEwRnF3Zm5mNTc2NHI2WTVXbEFUWDE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Enliven Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPLXdTaGl3X3MzZ2JVTHd4TEFraHlXZGE1WG11QmxWdldvTEJrYzlodHI1cGd1YWJPWVpYQnlpNWU4YjFUMXY1N191TE1zNUNyMElRb3o1TEROd0RWaUkyb25Gb3lQckQ0Z0VyekhuQXdfV2xpajB4MW5YRk5BbUdaVTM5QWh3cjNPSVdjUDRSWDVydEY0bHVpbzVlQzRsaE10OXkw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQVmt5N29DOEh4MjFuQUg0ejh5LVRKR2dLMWdWT2o5SkxzeklINWpOTEFKX3AyQ1FROXlPbXB3LVVhSjBFRmlOZU9GMHdCenBPN2xhOUcwZDZ4RzN3RzRsSm42VjRyYk1tQnNpb0tPYlQtQ2RwWHVTejlidEdabDRsci1YLTFnMHZpbVJNVDd3YVJ2SzR2YXRYWnY5WmJ0eXNGMUhXeFc2ZjlId0JB?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxQQ3pyUEpka1lzTzhjOUVoZ0hGYUZMRDI1VDl5SVFDRTl0MkFXRUtkZDlYZXpQZUo4c3ktVGRVY1FHc1UwVE5lYVh4aFZGdkdELWdhTzhZam1hTjlPLVdtZU10bVhLNGU4eU9WblRBbnJzZjlwMmxZcW5TX0E4SWJXdXUtam1NLXFwMjRET2FDTTFiQ0c0ZUNpSHhqR2k0Z21KRkhNYkt1SXFNaXpTMllnNGpmZmc2UTY1eE0yRXk1d2N3ekVYanM3dXJYV2JKRXFIVm9wMkVoRGVZY1ZaanFEMm9ud0RDaDEtV0cyMF9qUHVMbmtjRDQ3TThMVlVZekpubXNJXzhoNUhpU3o3cldYSWlOaDZFQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Enliven prices ~$400 million stock and warrant sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcVp4Q0hRanRwaG5KVXRpMkdOQlZ4U005Vm9qVmhDSks2Y2hvQWJVd3R0MmdvdWlvYUF3RV9EUEE1dnQ5UlVWZm9LNHl0aGRBLW12Q2xaVmtCdWJ5MzJUOFhQdFR5Zm1uSjFRanhsQlIzS01JUmRITTVVWm9GeWdqWWhWSW1YUGx0eXJ2eW4tOV8zM1o3dGxCSVc2U3VGWlRLd0t3WjQwUWN0QVhHdW9tNC10WmNLdWNuZmU5T1VvNkQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxPS1Z3MFcxSnhhc0tZaTZoT1RSSjRpay05ZS1weEdETjlpRUxHUWQ0MjhGZFRRYkYzNnNwMXpNLWt5eEo1Mks0Vk14b1IzZm10UjY2LTh6WXJtV1ZCYVVqb1VQaWFHSVRGNWh6a3hVYlRTaXRvZUdrRl9FZmJWSlExWkUwTjZ6S2tNOUVuUjV0aXBubVpsR0tfZ0lGaXdUSm0tMVNtZ0RhZnctNThjYjNycjg2MGlhczRlYVNnQlBGV2Rvckc1N2dOTGdLbXFBLTU0X2hTMTZRNnl5QmJWOWhVOUZuWWNRa0ZuSk5kT3ozMTRDemM?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNdmpYclBULW9jVzJzaFFvclFmaXFOcmlZZE01QUNXNnM0YTUtSGxQOTRqcVY2XzJXZnFkdVFpc1d0b09QNFVkSDhEMHctMzZ6R0NBSWR5SkJ2MV9KMHNqbWJNdkM0Qi1GZWZrYm5HYWdNcEZWSkdKM3N0ZkdJVDNDR2FZUE9FZlVDeDdXQW90aDVfeEkxN3JVQVdvTzZ6NWdjcVBld3hySjd4VmJxLV84V2ZYazI1dHZWQklhZ1dUUXhfWkJJLXJiMjh3eUtrYlNBdzdyRVpaOFAxWWN5cEEtNjdEbG1Ldw?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Enliven Therapeutics (ELVN) Valuation As ENABLE Trial Data Update Nears", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPWEJKMTE2aWg2NHowV3JXOFpmcG4yZDQ1QTB2dmZmakRhM2lGOGV4a2dPYUJ4TEtGOThqQ0hYQXpOdFowdE5zTzRVaC05RjhoVmRMN09sWERHaHdpS1JvTFdaMElOSmN0emtVUTVfYlNENlFEVEJ6THhnT3g2Q1VrTWlFV2tBcjZXY2dRZDdiUGRUTjdNRER2UXM5LUl4THlsVGxnYkU2VW5zbWlJUnc?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxONXBDN3d2d0dOcGVpWGRNWXZ3YkVZMm9KUGlZa1BTRlpHam03dzhtNTNXMkJxQVpNU1JXM3lJUkQ1NmdteTFLVGxybm5HWHA3S2V1VzN1RmptRXljdktCUE9EWW9ta0FoSktzOEV4d1VyQ2dnVmk4bDZKaWhueDdrbHdNRnpYelRpSl9LX0l3aUNqNlNCRUZmVW9IbzRLdEFLU2g2dnZiZDlHaXkzQk5CNHFWVFNsajNGYzlCNmJmX2pNcVhUdXdlSm9KOThRTjVSM0NYMTNGTTgxU1Z1OGJ2bw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPTzhwSTdkak9TSURWYVQ2NkZZRmF0anlfemJDRmhxdDhxdFBaMEtNWFVWbmh3TWVHU0tDbWdINlZoNHFsY1EtaDFzNk0wem10LUxMUzlDU2JEYlRibENwNVFQclprb1pUS3ZYVDV0b19HNWMwaWNyS3lVN2xfX3NSS1FVRUJfQ1JTeVRDdW5FM1ZZa0Q2SHA2WkNrc09BMkFoZ1Zn?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOU1JxUHZ4UV9vVlRvTnhrYUZ4M2Z6OThuOFhSb2ozbkVoa3p3VV9IV0RGOGxIUnhGVTFYZ2hDMFV4VHdvcGwwZmlVdlZfOTU0bFhoMkQ1c1lQUmNWTlZJSk1LR01JcTg5Sm5qTGdkTTJZOUdLcVozdG5WcGhmVUJuUTJzcVBkdmRZYmlTMmdrUVJRSjRIdFZ5NGxHdVJKaTBLbDQ2Ul8taURCQjF4TkVB?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Terns Buyout Deal Ignites Optimism For Enliven Therapeutics\u2019s Blood Cancer Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOMEZUWHB0SWthT1pFOFVlNU03OEpneTZJRmh4TzN2MW5PUHpIN3ExelZvZ0Z3MUQ4WDR0MkVDa3hNQ1lBTDFtai1iMnBZMzh0eWIzYUswZFpKMU56YTE2U1RSS0wxdE5PRHRrNzQ2SWNTYkZHVzdCNFQzUWtyMmVod1loVjdvc21GYTFvMXR4Q0tyYlYxaHRXTU1Ha3l0UlB4OVRYWmVvN3BNTE92S1owNkx0OHktNm9nQzVvYTNvRHNmRUNhbXAzYjdmUlJnWlJHa2JSN3ltc3dpS0JMSVVZ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts \u2018Upbeat\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZzdhZUFjRWMwT0FyNlktQTdRU0Jna0pfM1BkM2JNWTFUUl8yeE1mSWVMMlJFZHdzTE15dkhmNkdaSXNzX0QyMV9qeG9MM3k3NzJwSUtBZmV5NE5QZGF0WEw4anlBcVowbFUxZ2tQOURhY2FKa2RidjhMOUlqcVQxdXNXZjBILW84LVNDdXdNNHFROTcxWVRfZGRUWnY2Nmc?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAJBVV95cUxNT1JyNDdnZVhPMkNMMjRiNENmWnQxUVlwTFdaX0pfdkVPMFNyTy1fUFZjdEdwU01WTnptY0dhS3RISHo5WUZsSVlwMm1majlYYm1BNlN1cFoxU3dVRzlYQVdOY0hLNGo5Q2c3NTQyQ2pKeHFNMWNfX0RNXzZKMWM2T3FQaXJ1aWZfa19BTGh2dnhMcEUzOXAzNVF2SG9MS29lTW9HU0RiVkdmNG5uQ0VoemVBb3RxOWVhU3NjQi1CSTMzNExuejFKa3hpMVlJdk9uTXdva3dSNkdaWGJ4MWZsTDBMNTE4b29DR3VhNXlXS2l1emloY0VVV0F5UGYxelozcE05Z0g4d1dycTRKLURHVnZQcHlGaTlreVdLMnkwcUwwYVdnd1FGWU05UFBtMWpCYnR3YjNnQ2pIWXFOWUdXNW83U0NVNUdtd0VsVw?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-16T07:00:00+00:00", "published_display": "16 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enliven Therapeutics stock hits 52-week high at 52.47 USD", "summary": "Enliven Therapeutics (ELVN) has reached a new 52-week high of $52.47, reflecting a significant year-to-date return of 236% and a 143.2% increase over the past year. Despite this surge, InvestingPro data suggests the stock appears overvalued relative to its Fair Value. The company", "url": "https://www.investing.com/news/company-news/enliven-therapeutics-stock-hits-52week-high-at-5247-usd-93CH-4793950", "source_name": "Investing.com", "published_at": "2026-07-15T17:11:44", "published_display": "15 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64", "summary": "H.C. Wainwright has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and increased the target price to $64. This indicates a positive outlook from the analyst firm regarding the company's future performance and stock value.", "url": "https://www.moomoo.com/news/post/72710505/hc-wainwright-maintains-enliven-therapeutics-elvnus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-11T04:11:44", "published_display": "11 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Enliven Therapeutics price target on trial data By Investing.com", "summary": "H.C. Wainwright increased its price target for Enliven Therapeutics (NASDAQ:ELVN) to $65 from $56, maintaining a Buy rating, following positive Phase 1 trial data for ELVN-001 in chronic myelogenous leukemia. The stock has seen a significant year-to-date surge, and analysts hold ", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-raises-enliven-therapeutics-price-target-on-trial-data-93CH-4727142", "source_name": "Investing.com Canada", "published_at": "2026-07-09T11:41:12", "published_display": "09 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Fell Out Of Russell Indexes, But Is The Valuation Already Rich?", "summary": "Enliven Therapeutics (ELVN) was recently removed from several Russell indexes, yet its share price has seen significant gains. Despite trading below the average analyst target, the company's Price-to-Book ratio of 7.8x is well above the industry average, suggesting a rich valuati", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-fell-out-of-russell-indexes-but-is", "source_name": "Simply Wall Street", "published_at": "2026-07-09T01:40:23", "published_display": "09 Jul 2026 01:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/enliven-therapeutics-insider-sold-shares-212154684.html", "source_name": "MT Newswires", "published_at": "2026-07-08T21:21:54+00:00", "published_display": "08 Jul 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) director sells 10,000 shares under 10b5-1 plan", "summary": "Enliven Therapeutics director Lori Anne Kunkel sold 10,000 shares of common stock on July 6, 2026, through two open-market transactions at weighted average prices of $50.8442 and $49.9834 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan establis", "url": "https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-ce6296e72f95.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:40:23", "published_display": "08 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Enliven Therapeutics Inc. (ELVN) Affects Rotational Strategy Timing", "summary": "This article analyzes Enliven Therapeutics Inc. (NASDAQ: ELVN) using AI models to determine its impact on rotational strategy timing. It highlights a near-term neutral sentiment amidst mid and long-term strength, identifying a mid-channel oscillation pattern and a significant ris", "url": "https://news.stocktradersdaily.com/news_release/1/How_Enliven_Therapeutics_Inc._ELVN_Affects_Rotational_Strategy_Timing_070726022202_1783405322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T02:22:00", "published_display": "07 Jul 2026 02:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Enliven Therapeutics Inc (ELVN)", "summary": "This article examines the historical performance of investing $1,000 in Enliven Therapeutics Inc (ELVN) over various timeframes, detailing the significant returns an investor would have seen. It also provides an in-depth company profile, outlining Enliven Therapeutics' focus on p", "url": "https://www.stocktitan.net/tools/stock-return-calculator/ELVN", "source_name": "Stock Titan", "published_at": "2026-07-04T08:09:10", "published_display": "04 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQSmUyaExTdlp0YzVEQUhncjVoeTNiRTR6cDJUalY2WUdwMk9KRUF6bGpMMk14aWlUU3Bud2FWbzFFaGRCRWhsMUdhZUtTWVg0bHlfVkZMVm5HZGF2dVJTemQ0RGFJSExrM3RnV3BQdzRMVDJRNWNnYkdRVFdNb3I0NEx0eFZsb3VyY1pIODJFUUVlM1BIbjVhSTE1VWpxMXhzMU9oNA?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELVN Maintained by Stifel -- Price Target Raised to $80", "summary": "Stifel maintained a \"Buy\" rating for Enliven Therapeutics (ELVN) and raised its price target from $60 to $80 on July 1, 2026, indicating optimism about the company's future. Despite this positive analyst outlook, ELVN has a low GF Score\u2122 of 28/100, primarily due to weak profitabi", "url": "https://www.gurufocus.com/news/8941185/elvn-maintained-by-stifel-price-target-raised-to-80", "source_name": "GuruFocus", "published_at": "2026-07-01T14:40:07", "published_display": "01 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jones Trading raises Enliven Therapeutics price target on CML trials By Investing.com", "summary": "Jones Trading has increased its price target for Enliven Therapeutics (NASDAQ:ELVN) to $70 from $45, reiterating a Buy rating. This adjustment follows a positive Phase I trial update for ELVN-001 in chronic myeloid leukemia (CML) and the company's decision to pursue first-line an", "url": "https://ng.investing.com/news/stock-market-news/jones-trading-raises-enliven-therapeutics-price-target-on-cml-trials-93CH-2577860", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T00:11:55", "published_display": "30 Jun 2026 00:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jones Trading raises Enliven Therapeutics price target on CML trials", "summary": "Jones Trading increased its price target for Enliven Therapeutics (NASDAQ:ELVN) from $45 to $70, while maintaining a Buy rating, based on a positive Phase I update for its CML trials. The biotech company's stock has surged 214% in six months, and Jones Trading revised its model t", "url": "https://www.investing.com/news/analyst-ratings/jones-trading-raises-enliven-therapeutics-price-target-on-cml-trials-93CH-4765132", "source_name": "Investing.com", "published_at": "2026-06-29T23:10:36", "published_display": "29 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%", "summary": "", "url": "https://finance.yahoo.com/m/485cc147-72f1-3755-90ef-1f9d33a6bec5/what-to-know-about-this.html", "source_name": "Motley Fool", "published_at": "2026-06-27T19:56:42+00:00", "published_display": "27 Jun 2026 19:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally", "summary": "OrbiMed Advisors, a significant shareholder in Enliven Therapeutics (NASDAQ: ELVN), recently sold 860,123 shares worth approximately $39 million. This sale represents an 11.60% reduction in their indirect holdings but still leaves OrbiMed as a major shareholder with over 6.5 mill", "url": "https://finance.yahoo.com/markets/stocks/articles/know-orbimeds-39-million-enliven-162312437.html", "source_name": "Market source", "published_at": "2026-06-27T12:23:00", "published_display": "27 Jun 2026 12:23", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics, Inc. Actuals & Estimates (NASDAQ:ELVN)", "summary": "This article provides an overview of Enliven Therapeutics, Inc. (NASDAQ: ELVN) stock performance, financial data, and analyst forecasts. It includes current stock price, historical highs and lows, market capitalization, earnings per share, revenue, and upcoming earnings report da", "url": "https://www.tradingview.com/symbols/NASDAQ-ELVN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:12", "published_display": "26 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELVN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and various financial metrics for Enliven Therapeutics, Inc. (ELVN) stock. It includes analyst price targets, historical price performance, volatility, market capitalization, upcoming earnings dates, and past financial results like EPS and revenue", "url": "https://www.tradingview.com/symbols/NASDAQ-ELVN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:12", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "22% Below Analyst Target, Is Enliven Therapeutics (ELVN) Fairly Valued Here", "summary": "Enliven Therapeutics (ELVN) is currently valued at US$2.9 billion with shares at US$49.12, showing strong recent performance. Despite being loss-making and having a value score of 2, its Price-to-Book ratio of 6.6x is below its peer average but significantly above the broader US ", "url": "https://www.sahmcapital.com/news/content/22-below-analyst-target-is-enliven-therapeutics-elvn-fairly-valued-here-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-25T10:10:57", "published_display": "25 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed funds trim Enliven Therapeutics (NASDAQ: ELVN) stake with 860K-share sale", "summary": "OrbiMed-affiliated entities have reduced their stake in Enliven Therapeutics (NASDAQ: ELVN) by selling 860,123 shares on June 22, 2026, at prices ranging from $45 to $45.38 per share. Despite this sale, the funds still retain significant indirect holdings, with one fund holding o", "url": "https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-d05427e0374a.html", "source_name": "Stock Titan", "published_at": "2026-06-25T00:41:20", "published_display": "25 Jun 2026 00:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed entities sell $39 million in Enliven Therapeutics stock", "summary": "OrbiMed entities, including OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital GP VII LLC, sold approximately $39 million worth of Enliven Therapeutics (NASDAQ:ELVN) common stock on June 22, 2026. The sale involved 860,123 shares at prices between $45.00 and $45.38", "url": "https://www.investing.com/news/insider-trading-news/orbimed-entities-sell-39-million-in-enliven-therapeutics-stock-93CH-4759435", "source_name": "Investing.com", "published_at": "2026-06-24T23:41:20", "published_display": "24 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed cuts Enliven Therapeutics (ELVN) holdings to 9.5% of shares", "summary": "OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Enliven Therapeutics (ELVN) to 9.5% of outstanding shares, as reported in an Amendment No. 5 to their Schedule 13D filing. This reduction stems from open-market sales of Enliven shares by OPI VII,", "url": "https://www.stocktitan.net/sec-filings/ELVN/schedule-13d-a-enliven-therapeutics-inc-amended-major-shareholder-rep-2b58ce8978a9.html", "source_name": "Stock Titan", "published_at": "2026-06-24T23:41:20", "published_display": "24 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?", "summary": "Orbimed Advisors, a medical and biotech-focused hedge fund, recently sold 281,408 shares of Enliven Therapeutics Inc. (ELVN) for approximately $12.67 million, representing 3.67% of its indirect holdings. This transaction follows the biotech company's announcement of promising dat", "url": "https://www.fool.com/coverage/filings/2026/06/24/medical-hedge-fund-sells-281-000-shares-of-enliven-theapeutics-is-it-time-to-sell-elvn/", "source_name": "The Motley Fool", "published_at": "2026-06-24T19:39:24", "published_display": "24 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Enliven Therapeutics, Inc. Stocks", "summary": "This article lists various ETFs that invest in Enliven Therapeutics, Inc. (ELVN) stocks, providing detailed information such as market value, weight, issuer, management style, expense ratio, and assets under management for each fund. The ETFs primarily focus on small-cap, health ", "url": "https://www.tradingview.com/symbols/NASDAQ-ELVN/etfs/", "source_name": "TradingView", "published_at": "2026-06-24T02:39:24", "published_display": "24 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics stock hits 52-week high at 48.55 USD", "summary": "Enliven Therapeutics Inc. has achieved a significant milestone, with its stock reaching a 52-week high of $48.55 and currently trading at $48.72, boasting a 198% year-to-date return. This strong performance is supported by recent successful public offerings totaling around $460 m", "url": "https://m.uk.investing.com/news/stock-market-news/enliven-therapeutics-stock-hits-52week-high-at-4855-usd-93CH-4740977?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T21:10:48", "published_display": "23 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics CFO Hohl sells $263,577 in stock", "summary": "Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of the company's common stock for $263,577 on June 17, 2026, executed under a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high, generating a 193% year-to-date return. Prior to t", "url": "https://www.investing.com/news/insider-trading-news/enliven-therapeutics-cfo-hohl-sells-263577-in-stock-93CH-4754069", "source_name": "Investing.com", "published_at": "2026-06-23T08:10:48", "published_display": "23 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) CFO sells 6,018 shares after option exercise", "summary": "Enliven Therapeutics (ELVN) CFO Benjamin Hohl exercised stock options for 6,018 shares at $2.48 each and subsequently sold all 6,018 shares in open-market transactions on June 17, 2026, at weighted average prices between $42.79 and $44.75. These transactions were executed under a", "url": "https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-d881b9ab7a77.html", "source_name": "Stock Titan", "published_at": "2026-06-23T08:10:48", "published_display": "23 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Insider Sold Shares Worth $263,577, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/enliven-therapeutics-insider-sold-shares-211853820.html", "source_name": "MT Newswires", "published_at": "2026-06-22T21:18:53+00:00", "published_display": "22 Jun 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Enliven Therapeutics Inc For: 22 June By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Enliven Therapeutics Inc. on June 22. It is a brief, one-line report with a reference to Reuters. The article includes various market data, news headlines, and promotional content from Investing.com.", "url": "https://ca.investing.com/news/stock-market-news/form-4-enliven-therapeutics-inc-for-22-june-93CH-4702014", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:41:20", "published_display": "22 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics CMO sells $219,016 in shares", "summary": "Helen Louise Collins, CMO of Enliven Therapeutics (NASDAQ:ELVN), sold 4,900 shares for $219,016 on June 17, 2026, executed under a Rule 10b5-1 trading plan. These sales followed the exercise of stock options for 5,000 shares. The company's stock is trading near its 52-week high a", "url": "https://www.investing.com/news/insider-trading-news/enliven-therapeutics-cmo-sells-219016-in-shares-93CH-4754070", "source_name": "Investing.com", "published_at": "2026-06-22T21:41:19", "published_display": "22 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) CMO exercises 5,000 options and sells 5,000 shares", "summary": "Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised 5,000 stock options at $2.48 per share and subsequently sold 5,000 shares of common stock in three open-market transactions on June 17, 2026. The sales were conducted under a pre-arranged Rule 10b5-1 tra", "url": "https://www.stocktitan.net/sec-filings/ELVN/form-4-enliven-therapeutics-inc-insider-trading-activity-c568aee93b0f.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:41:19", "published_display": "22 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polar Capital (NASDAQ: ELVN) reports 8.46% stake in Enliven Therapeutics", "summary": "Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have jointly reported an 8.46% beneficial ownership stake in Enliven Therapeutics (NASDAQ: ELVN). This stake amounts to 5,056,807 shares of common stock, based on Enliven Therapeutics'", "url": "https://www.stocktitan.net/sec-filings/ELVN/schedule-13g-a-enliven-therapeutics-inc-amended-passive-investment-di-0e62afd9ab3a.html", "source_name": "Stock Titan", "published_at": "2026-06-22T13:40:12", "published_display": "22 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELVN (Nasdaq) selling holders report proposed sale, recent 272,322-share disposition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNcmROUE1ITWJjRnBnNzcteXpOLXlzR3VydDREaEhpTWs1eXFNajdRVTBXVGJ5YUZOSzNSQnNxcC1lVl92bHNybjlrNF9Qb0ktN25DWVh2WVVSUV9ORW9JbVNnQkpTQndxWlNIbWFUTGJjemJMTHQyeDJ2ZWh1RGNCZjZ2NEZXX3VpaDdxWjVmYzI1SVJMSGNVdEtfeHVIYUNESzVz?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed funds trim Enliven Therapeutics (ELVN) stake with 281,408-share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNWnNDYUlZUTBqbElUNThQTTFRVWM3d19BY3BCNGJ2YXJnZTdUNUFUQTBvNkNPSi11aE0zQm10RG1hdlB5SEpaQ1F5RnVSZjBybUoxWmFQQWdvamdabFVhV3N6ZEMzZGdRQ1llcnlqRlVBVVFVaHY0TzVhbXZYTi1PSEJmZmZOUmRuOG16UzNMR3ZBUXlUS0dPa3J4TDlIT3RKZ2FfMjZsaDJXU25hQTNmajk3WklDWEc4ZHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Closes Upsized $460 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enliven-therapeutics-closes-upsized-460-210131835.html", "source_name": "MT Newswires", "published_at": "2026-06-15T21:01:31+00:00", "published_display": "15 Jun 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wJBVV95cUxPSWZ3TkoxUDN0bjVMZnNCdXhGejBxWXZCS0I5NnpHRGhvOFVDdjJJa19IamYyWDktZ1BJanl5VldXNTlWdHhVQ3Q1akhnZFA3RXdLamVDZ1dEWnowVS1Da2pKWmF6cUg3QUdWbzk2YzlzMUgwWEt5QzUxT1BONWgybEdSaWFScENGRExiMHBHcHdvZEd3THBTSk45OFdYNkEyeTdOMFNoMzhhQWd4dzVPNEZSaG9rWTlWYmV4OG1lTFNsVDB4aEUyQ2x5Z3N3YXZyZy1Nb2ZrT2hWTEJpc2Q5ZHNHcW0xM0s5Q0xNckxZaWdreThIaVZkS25oSE1ZVHZ1NVd1MHVKWFJJOU9pb3E5eUVveXNXVkY2bnkyV0tYamswTUgzT0puNy1PWlRJTVhDVTNKUFM4S2VpbzdrUU1tVkFmRGt5QmM5c2xScmJxekVaamZ0RGJ3?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Enliven just raised $460M in stock and warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQdWRoclo0UXBwckt0VUhiYVBDYnM1N19jb3JhbHFUYVUzTDUzM0dHMzRKMG1rUkQyMjJUR3h2WDFxS0F3Z2FqMFRMNnVEeVJiVUtxUzZLU09VNkJEZ3U4VUJYQ0U4TXpMU0dRY0Q3d05wRFVfOU9WUjNBRVpNbW5sVkpjNVZENEZqcW5BaHVrMFp5Z0dNYzIxWXlORkFuWWt0MFZPQ1BQSzV4MnEwRnF3Zm5mNTc2NHI2WTVXbEFUWDE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Enliven Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPLXdTaGl3X3MzZ2JVTHd4TEFraHlXZGE1WG11QmxWdldvTEJrYzlodHI1cGd1YWJPWVpYQnlpNWU4YjFUMXY1N191TE1zNUNyMElRb3o1TEROd0RWaUkyb25Gb3lQckQ0Z0VyekhuQXdfV2xpajB4MW5YRk5BbUdaVTM5QWh3cjNPSVdjUDRSWDVydEY0bHVpbzVlQzRsaE10OXkw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQVmt5N29DOEh4MjFuQUg0ejh5LVRKR2dLMWdWT2o5SkxzeklINWpOTEFKX3AyQ1FROXlPbXB3LVVhSjBFRmlOZU9GMHdCenBPN2xhOUcwZDZ4RzN3RzRsSm42VjRyYk1tQnNpb0tPYlQtQ2RwWHVTejlidEdabDRsci1YLTFnMHZpbVJNVDd3YVJ2SzR2YXRYWnY5WmJ0eXNGMUhXeFc2ZjlId0JB?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxQQ3pyUEpka1lzTzhjOUVoZ0hGYUZMRDI1VDl5SVFDRTl0MkFXRUtkZDlYZXpQZUo4c3ktVGRVY1FHc1UwVE5lYVh4aFZGdkdELWdhTzhZam1hTjlPLVdtZU10bVhLNGU4eU9WblRBbnJzZjlwMmxZcW5TX0E4SWJXdXUtam1NLXFwMjRET2FDTTFiQ0c0ZUNpSHhqR2k0Z21KRkhNYkt1SXFNaXpTMllnNGpmZmc2UTY1eE0yRXk1d2N3ekVYanM3dXJYV2JKRXFIVm9wMkVoRGVZY1ZaanFEMm9ud0RDaDEtV0cyMF9qUHVMbmtjRDQ3TThMVlVZekpubXNJXzhoNUhpU3o3cldYSWlOaDZFQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Enliven prices ~$400 million stock and warrant sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcVp4Q0hRanRwaG5KVXRpMkdOQlZ4U005Vm9qVmhDSks2Y2hvQWJVd3R0MmdvdWlvYUF3RV9EUEE1dnQ5UlVWZm9LNHl0aGRBLW12Q2xaVmtCdWJ5MzJUOFhQdFR5Zm1uSjFRanhsQlIzS01JUmRITTVVWm9GeWdqWWhWSW1YUGx0eXJ2eW4tOV8zM1o3dGxCSVc2U3VGWlRLd0t3WjQwUWN0QVhHdW9tNC10WmNLdWNuZmU5T1VvNkQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxPS1Z3MFcxSnhhc0tZaTZoT1RSSjRpay05ZS1weEdETjlpRUxHUWQ0MjhGZFRRYkYzNnNwMXpNLWt5eEo1Mks0Vk14b1IzZm10UjY2LTh6WXJtV1ZCYVVqb1VQaWFHSVRGNWh6a3hVYlRTaXRvZUdrRl9FZmJWSlExWkUwTjZ6S2tNOUVuUjV0aXBubVpsR0tfZ0lGaXdUSm0tMVNtZ0RhZnctNThjYjNycjg2MGlhczRlYVNnQlBGV2Rvckc1N2dOTGdLbXFBLTU0X2hTMTZRNnl5QmJWOWhVOUZuWWNRa0ZuSk5kT3ozMTRDemM?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNdmpYclBULW9jVzJzaFFvclFmaXFOcmlZZE01QUNXNnM0YTUtSGxQOTRqcVY2XzJXZnFkdVFpc1d0b09QNFVkSDhEMHctMzZ6R0NBSWR5SkJ2MV9KMHNqbWJNdkM0Qi1GZWZrYm5HYWdNcEZWSkdKM3N0ZkdJVDNDR2FZUE9FZlVDeDdXQW90aDVfeEkxN3JVQVdvTzZ6NWdjcVBld3hySjd4VmJxLV84V2ZYazI1dHZWQklhZ1dUUXhfWkJJLXJiMjh3eUtrYlNBdzdyRVpaOFAxWWN5cEEtNjdEbG1Ldw?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Enliven Therapeutics (ELVN) Valuation As ENABLE Trial Data Update Nears", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPWEJKMTE2aWg2NHowV3JXOFpmcG4yZDQ1QTB2dmZmakRhM2lGOGV4a2dPYUJ4TEtGOThqQ0hYQXpOdFowdE5zTzRVaC05RjhoVmRMN09sWERHaHdpS1JvTFdaMElOSmN0emtVUTVfYlNENlFEVEJ6THhnT3g2Q1VrTWlFV2tBcjZXY2dRZDdiUGRUTjdNRER2UXM5LUl4THlsVGxnYkU2VW5zbWlJUnc?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxONXBDN3d2d0dOcGVpWGRNWXZ3YkVZMm9KUGlZa1BTRlpHam03dzhtNTNXMkJxQVpNU1JXM3lJUkQ1NmdteTFLVGxybm5HWHA3S2V1VzN1RmptRXljdktCUE9EWW9ta0FoSktzOEV4d1VyQ2dnVmk4bDZKaWhueDdrbHdNRnpYelRpSl9LX0l3aUNqNlNCRUZmVW9IbzRLdEFLU2g2dnZiZDlHaXkzQk5CNHFWVFNsajNGYzlCNmJmX2pNcVhUdXdlSm9KOThRTjVSM0NYMTNGTTgxU1Z1OGJ2bw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPTzhwSTdkak9TSURWYVQ2NkZZRmF0anlfemJDRmhxdDhxdFBaMEtNWFVWbmh3TWVHU0tDbWdINlZoNHFsY1EtaDFzNk0wem10LUxMUzlDU2JEYlRibENwNVFQclprb1pUS3ZYVDV0b19HNWMwaWNyS3lVN2xfX3NSS1FVRUJfQ1JTeVRDdW5FM1ZZa0Q2SHA2WkNrc09BMkFoZ1Zn?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOU1JxUHZ4UV9vVlRvTnhrYUZ4M2Z6OThuOFhSb2ozbkVoa3p3VV9IV0RGOGxIUnhGVTFYZ2hDMFV4VHdvcGwwZmlVdlZfOTU0bFhoMkQ1c1lQUmNWTlZJSk1LR01JcTg5Sm5qTGdkTTJZOUdLcVozdG5WcGhmVUJuUTJzcVBkdmRZYmlTMmdrUVJRSjRIdFZ5NGxHdVJKaTBLbDQ2Ul8taURCQjF4TkVB?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Terns Buyout Deal Ignites Optimism For Enliven Therapeutics\u2019s Blood Cancer Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOMEZUWHB0SWthT1pFOFVlNU03OEpneTZJRmh4TzN2MW5PUHpIN3ExelZvZ0Z3MUQ4WDR0MkVDa3hNQ1lBTDFtai1iMnBZMzh0eWIzYUswZFpKMU56YTE2U1RSS0wxdE5PRHRrNzQ2SWNTYkZHVzdCNFQzUWtyMmVod1loVjdvc21GYTFvMXR4Q0tyYlYxaHRXTU1Ha3l0UlB4OVRYWmVvN3BNTE92S1owNkx0OHktNm9nQzVvYTNvRHNmRUNhbXAzYjdmUlJnWlJHa2JSN3ltc3dpS0JMSVVZ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts \u2018Upbeat\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZzdhZUFjRWMwT0FyNlktQTdRU0Jna0pfM1BkM2JNWTFUUl8yeE1mSWVMMlJFZHdzTE15dkhmNkdaSXNzX0QyMV9qeG9MM3k3NzJwSUtBZmV5NE5QZGF0WEw4anlBcVowbFUxZ2tQOURhY2FKa2RidjhMOUlqcVQxdXNXZjBILW84LVNDdXdNNHFROTcxWVRfZGRUWnY2Nmc?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAJBVV95cUxNT1JyNDdnZVhPMkNMMjRiNENmWnQxUVlwTFdaX0pfdkVPMFNyTy1fUFZjdEdwU01WTnptY0dhS3RISHo5WUZsSVlwMm1majlYYm1BNlN1cFoxU3dVRzlYQVdOY0hLNGo5Q2c3NTQyQ2pKeHFNMWNfX0RNXzZKMWM2T3FQaXJ1aWZfa19BTGh2dnhMcEUzOXAzNVF2SG9MS29lTW9HU0RiVkdmNG5uQ0VoemVBb3RxOWVhU3NjQi1CSTMzNExuejFKa3hpMVlJdk9uTXdva3dSNkdaWGJ4MWZsTDBMNTE4b29DR3VhNXlXS2l1emloY0VVV0F5UGYxelozcE05Z0g4d1dycTRKLURHVnZQcHlGaTlreVdLMnkwcUwwYVdnd1FGWU05UFBtMWpCYnR3YjNnQ2pIWXFOWUdXNW83U0NVNUdtd0VsVw?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-16T07:00:00+00:00", "published_display": "16 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 56, "sentiment_summary": {"positive": 15, "negative": 7, "neutral": 34, "score": 55, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}], "positive_events": 15, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 51.09, "latest_week": "2026-07-10", "one_week_move": 2.5, "four_week_move": 10.8, "twelve_week_move": 6.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.364779, "market_dynamics_buy_signal": false, "relative_strength": 55.010767, "fair_value_gap": 126.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 43.2803, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.5% over one week, +10.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 12}, {"label": "Investing.com", "count": 6}, {"label": "PR Newswire", "count": 6}, {"label": "TradingView", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Investing.com Canada", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 7}, {"label": "Deals and strategy", "count": 4}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.5% over one week, +10.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enliven Therapeutics stock hits 52-week high at 52.47 USD"}], "updated_at": "2026-07-16T15:23:39.470050+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}